Plus Therapeutics (NASDAQ:PSTV) reported positive data from the ReSPECT-LM clinical study evaluating the company’s lead radiotherapeutic, rhenium (Re-186) obisbemeda, for the treatment of leptomeningeal metastases (LM) at ASCO’s Society for Neuro Oncology in San Francisco.
The dose escalation study demonstrated preliminary safety and efficacy results, including median overall survival of 10 months for patients with LM, where cancer has spread to the membranes lining the brain and spinal cord.
“Based on the Phase 1 Part A data, we believe we can substantially dose escalate and develop a multiple dosing regimen that could yield meaningful clinical benefits including a survival benefit for the extremely tough clinical problem of leptomeningeal metastases,” Andrew Brenner, M.D., Ph.D., Professor of medicine, neurology, and neurosurgery at The University of Texas Health Science Center at San Antonio and principal investigator of the ReSPECT-LM clinical trial, said in a statement.
The FDA has approved continued dose escalation in the trial.
Marc Hedrick, M.D., president and CEO of Plus, said “Similar to our promising Phase 1 and 2 data for glioblastoma, this most recent data indicates that LM, which is ten times more common than glioblastoma, may be similarly addressable with targeted radiotherapy using Re-186 obisbemeda.”
